Lexington Biosciences, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced net loss was CAD 101,025 compared to CAD 563,192 a year ago. Basic loss per share from continuing operations was CAD 0.03 compared to CAD 0.15 a year ago. For the nine months, net loss was CAD 431,350 compared to CAD 2.088 million a year ago. Basic loss per share from continuing operations was CAD 0.11 compared to CAD 0.55 a year ago.